(Q36414518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

4

Jeffrey A Lieberman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Wayne M Alves

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Robert M Hamer

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

133-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd1956

17 January 2020

exact match

0 references

cites work

Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?

1 reference

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

Structural evaluation of the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

21 January 2018

1 reference

Randomized controlled trials in evidence-based mental health care: getting the right answer to the right question.

21 January 2018

1 reference

Placebo washout in trials of antipsychotic drugs

21 January 2018

1 reference

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

Content and quality of 2000 controlled trials in schizophrenia over 50 years

21 January 2018

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies

21 January 2018

1 reference

The new drug approvals of 1990, 1991, and 1992: trends in drug development

21 January 2018

1 reference

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

Trials: the next 50 years. Large scale randomised evidence of moderate benefits

21 January 2018

1 reference

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

21 January 2018

1 reference

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

21 January 2018

1 reference

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

31 March 2020

1 reference

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

31 March 2020

1 reference

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

31 March 2020

1 reference

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

31 March 2020

1 reference

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

31 March 2020

1 reference

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

31 March 2020

1 reference

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

31 March 2020

1 reference

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

31 March 2020

1 reference

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

31 March 2020

1 reference

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

31 March 2020

1 reference

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

31 March 2020

1 reference

Antipsychotic drug effects on brain morphology in first-episode psychosis

31 March 2020

1 reference

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

31 March 2020

1 reference

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

31 March 2020

1 reference

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

31 March 2020

1 reference

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

31 March 2020

1 reference

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

31 March 2020

1 reference

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

31 March 2020

1 reference

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

31 March 2020

1 reference

Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis

31 March 2020

1 reference

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

31 March 2020

1 reference

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

31 March 2020

1 reference

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

31 March 2020

1 reference

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

31 March 2020

1 reference

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

31 March 2020

1 reference

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

31 March 2020

1 reference

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

31 March 2020

1 reference

Schizophrenia trials: past, present and future

31 March 2020

1 reference

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

31 March 2020

1 reference

A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia

31 March 2020

1 reference

Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?

31 March 2020

1 reference

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

31 March 2020

1 reference

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

31 March 2020

1 reference

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

31 March 2020

1 reference

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

31 March 2020

1 reference

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

31 March 2020

1 reference

A meta-analysis of the efficacy of second-generation antipsychotics

31 March 2020

1 reference

Cost of innovation in the pharmaceutical industry

31 March 2020

1 reference

New drug development in the United States from 1963 to 1992

31 March 2020

1 reference

The new drug approvals of 1993, 1994, and 1995: trends in drug development.

31 March 2020

1 reference

The use of placebo control groups in the assessment of psychiatric drugs: an historical context.

31 March 2020

1 reference

Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk".

31 March 2020

1 reference

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

31 March 2020

1 reference

Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator

31 March 2020

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

31 March 2020

1 reference

Pragmatic randomised controlled trials in psychiatry

31 March 2020

1 reference

The case for practical clinical trials in psychiatry

31 March 2020

1 reference

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

31 March 2020

1 reference

Maximum-likelihood estimation for the mixed analysis of variance model

31 March 2020

1 reference

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

31 March 2020

1 reference

Effect of chlorpromazine on the behavior of chronically overactive psychotic patients.

31 March 2020

1 reference

CRITIQUE OF VIEWS OF THOMAS SZASZ ON LEGAL PSYCHIATRY

31 March 2020

1 reference

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1956

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16518380%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference